
Sign up to save your podcasts
Or


What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.
By HBR Presents / Brian Kenny4.5
190190 ratings
What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.

380 Listeners

1,453 Listeners

108 Listeners

1,844 Listeners

1,110 Listeners

3,993 Listeners

1,379 Listeners

747 Listeners

105 Listeners

174 Listeners

38 Listeners

810 Listeners

667 Listeners

219 Listeners

78 Listeners

166 Listeners

82 Listeners